Over the last few years, we have seen the approval of the first disease-modifying therapies for Alzheimer’s disease, signifying a poignant turning point for the field. The next generation of therapeutics and diagnostics promises to define the future of treatments – based on the biology of aging approach – with

In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.

Jan 10, 2025 · Mem­bers of Con­gress work­ing on an­ti-Chi­na leg­is­la­tion have asked the US Com­merce De­part­ment to hard­en its poli­cies around who can run clin­i­cal tri­als at sites …

reset password. We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours. email

Jan 6, 2025 · 2024’s novel drug approvals offered a wide array of new cancer drugs, rare disease treatments, a potential Alzheimer’s blockbuster, and about 10 fewer approvals than 2023. While 2022 and 2023 ...

Jan 10, 2025 · JPM agenda focuses on Trump 2.0 transition, market recovery & US-China dynamics, featuring talks with Sanofi's Ashrafian, ARCH's Nelsen, Scott Gottlieb & other leaders.

Biotech and pharma business news, with a focus on the science, people and money that drive the industry.

Jan 11, 2025 · Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, following months of setbacks by the smaller company that have led to a long ...

Jan 8, 2025 · A ba­by boy born with a de­bil­i­tat­ing ge­net­ic dis­ease will like­ly no longer re­quire a liv­er trans­plant to sta­bi­lize his con­di­tion, thanks to a first …

Jan 9, 2025 · There’s a shop­ping bo­nan­za for new obe­si­ty med­i­cines go­ing on among a mar­quee co­hort of bio­phar­ma in­vestors who are in-li­cens­ing treat­ment can­di­dates from Chi ...